查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2001055

新冠病毒即時檢測試劑盒市場：2026-2032年全球市場預測（按產品類型、檢測技術、檢體類型、分銷管道、應用和最終用戶分類）

COVID-19 Detection PoC Kits Market by Product Type, Detection Technology, Sample Type, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，COVID-19 檢測概念驗證試劑盒市場價值將達到 38.6 億美元，到 2026 年將成長至 41.4 億美元，到 2032 年將達到 62.8 億美元，複合年成長率為 7.18%。

主要市場統計數據
基準年 2025 38.6億美元
預計年份：2026年 41.4億美元
預測年份 2032 62.8億美元
複合年成長率 (%) 7.18%

這篇權威的介紹概述了疫情期間的快速創新如何在臨床環境和分散環境中發展成為一個複雜且永續的診斷生態系統。

新冠病毒檢測的概念驗證（PoC）試劑盒格局已從最初的緊急應變演變為診斷韌性中一個複雜且持久的組成部分。在疫情初期，快速檢測和緊急使用授權的開發優先考慮的是速度而非規模，但在隨後的幾年裡，穩健性、供應連續性和與臨床工作流程的整合變得至關重要。這種演化在產業內催生了一個多層次的生態系統，其中包括為各種環境（從集中式檢查室到分散式即時檢測點）設計的耗材、儀器和試劑盒。

對重新定義概念驗證(PoC) 測試、重塑診斷工作流程、供應鏈彈性和技術融合的關鍵結構性變化進行策略分析。

概念驗證 (PoC) 檢測試劑盒的格局正受到多項變革性變化的影響，這些變化共同重塑了相關人員制定檢測策略和產品開發的方式。首先，診斷工作流程的去中心化是一項核心挑戰。醫療系統和私人醫療機構越來越傾向於選擇能夠在傳統檢查室之外提供可靠結果的 PoC 解決方案，這促使製造商優先考慮以用戶為中心的設計、簡化的檢體採集流程以及與數位化報告平台的整合。隨著時間的推移，監管機構也調整了針對這些去中心化工具的核准流程。這加速了 PoC 的普及，同時也提高了人們對上市後監管和實際應用性能證據的期望。

對關稅主導的貿易趨勢如何重塑整個診斷供應鏈的採購、製造本地化和成本結構進行嚴格評估。

關稅措施的實施對新冠病毒檢測即時檢驗試劑盒的整個價值鏈產生了連鎖反應，影響到原料、成品以及跨境分銷策略。關稅改變了耗材和設備的到貨成本，促使製造商和採購團隊重新評估其籌資策略和庫存計劃。對於依賴海外生產的專用零件的製造商而言，關稅可能會促使其將生產轉移到近岸地區或與替代供應商建立合作關係。雖然這可能有助於提高長期抗風險能力，但短期內也可能需要投入資金進行流程認證。

以細分市場主導的綜合觀點，確定產品設計、監管證據和分銷策略的交集，最大限度地提高產品採用率和臨床效用。

細分市場分析為理解即時檢測試劑盒市場中創新、應用和商業性機會的交匯點提供了一個框架。從產品類型（耗材、儀器、試劑盒）的觀點來看，不同的營運和商業考量都會顯現出來。耗材需要大量、持續的供應和嚴格的品管；儀器需要論證資本投資的合理性並提供生命週期支援；而試劑盒則將試劑和說明書以針對特定使用環境最佳化的形式組合在一起。每個類別都有不同的採購週期和支援需求，這些都會影響供應商的市場進入策略。

詳細的區域分析解釋了法律規範、製造能力和醫療保健服務模式如何影響即時診斷解決方案的採用差異。

區域趨勢對概念驗證（PoC）診斷產品的開發、監管和部署有顯著影響。在美洲，法規結構的多樣性與完善的私人醫療保健網路和強大的購買力並存。這加速了先進即時檢測設備的部署，同時也催生了對價格適中的自測和監測工具的在局部需求。該地區龐大的國內製造業基礎可用於緩解供應鏈中斷，但都市區之間的醫療資源取得差異依然存在，因此需要採取差異化的分銷策略。

透過證據檢驗策略夥伴關係、平台模組化和整體解決方案的交付如何重新定義診斷開發領域的競爭優勢。

在即時檢測（PoC）領域，企業間的競爭行為以快速的產品改進、策略夥伴關係和靈活的經營模式為特徵。製造商正日益推行模組化平台策略，以便快速重新配置檢測方法和試劑，從而應對不斷變化的病原體生物學特性和市場需求。與試劑供應商、契約製造和軟體整合商建立策略夥伴關係，對於縮短產品上市時間和擴大分銷管道至關重要。

為領導者提供切實可行的策略建議，以建立具有韌性的供應鏈，增強以用戶為中心的設計，並調整經營模式以適應不斷變化的醫療保健需求。

產業領導者應採取多管齊下的策略，優先考慮供應鏈韌性、以使用者為中心的設計和策略性商業化，以充分掌握不斷成長的即時診斷（PoC）需求。首先，應透過選擇替代供應商、對關鍵試劑和組件採用雙重採購模式以及投資區域製造能力，實現供應鏈多元化並降低對單一供應商的依賴。這將有助於快速響應區域需求激增，同時降低貿易中斷和關稅波動帶來的風險。

我們高度透明的調查方法，結合對關鍵相關人員的訪談和嚴格的二次檢驗，在不依賴數值市場預測的情況下，產生可操作且符合道德規範的見解。

支持這些研究結果的調查方法結合了結構化的一手研究和系統的二手研究，以確保結果的可靠性和檢驗。一手研究的關鍵輸入包括對價值鏈上各相關人員（產品開發人員、採購負責人、臨床用戶、分銷合作夥伴和監管顧問）進行的半結構化訪談，以了解營運實際情況、產品推廣促進因素和未滿足的需求。這些訪談旨在引出可操作的決策標準以及影響採購和產品推廣選擇的實際限制因素。

將技術、供應鏈韌性和用戶訪問等方面的策略挑戰整合起來，得出簡潔的結論，有助於永續的決策。

總而言之，新冠病毒概念驗證（PoC）檢測領域已發展成為一個複雜的生態系統，其中技術、供應鏈、法規和使用者體驗相互作用，共同決定商業性和公共衛生結果。重點正從緊急部署轉向永續且具韌性的模式，以支援分散式檢查、強力的監測以及與醫療服務體系的整合。透過產品類型、應用、偵測技術、檢體類型、最終用戶和分銷管道等細分觀點，可以發現具體的創新和策略投資機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：新冠病毒檢測即時檢驗試劑盒市場：依產品類型分類

  • 消耗品
  • 裝置
  • 成套工具

第9章：依檢測技術分類的新冠病毒即時檢測試劑盒市場

  • 抗體
  • 抗原
  • LAMP

第10章：檢體類型分類的 COVID-19 檢測即時檢驗試劑盒市場

  • 鼻咽拭子
  • 口腔和咽拭子
  • 唾液

第11章：新冠病毒檢測即時檢驗試劑盒市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：新冠病毒檢測即時檢驗試劑盒市場：依應用領域分類

  • 臨床檢測
  • 研究
  • 自我檢查
  • 監視

第13章：新冠病毒檢測即時檢驗試劑盒市場：依最終用戶分類

  • 診斷中心
  • 居家照護
  • 醫院

第14章：新冠病毒即時檢測試劑盒市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：新冠病毒檢測即時檢驗試劑盒市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：新冠病毒檢測即時檢驗試劑盒市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國新冠病毒檢測即時檢驗試劑盒市場

第18章：中國新冠病毒檢測即時檢驗試劑盒市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Aurora Biomed Inc.
  • Becton Dickinson and company
  • BGI Group
  • BioFire Diagnostics
  • bioMerieux SA
  • Cerba HealthCare SAS by EQT
  • Co-Diagnostics, Inc.
  • Convergent Technologies GmbH & Co. KG
  • Cue health Inc.
  • DiaSorin SpA
  • Drummond Scientific Company
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Quest Diagnostics
  • Quidel Corporation
  • SD Biosensor Inc.
  • Seegene, Inc
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-205091A88F53

The COVID-19 Detection PoC Kits Market was valued at USD 3.86 billion in 2025 and is projected to grow to USD 4.14 billion in 2026, with a CAGR of 7.18%, reaching USD 6.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.86 billion
Estimated Year [2026] USD 4.14 billion
Forecast Year [2032] USD 6.28 billion
CAGR (%) 7.18%

An authoritative introduction framing how rapid pandemic-era innovation has matured into complex sustainable diagnostic ecosystems across clinical and decentralized settings

The COVID-19 detection proof-of-concept (PoC) kits landscape has evolved from an emergent emergency response into a nuanced and sustained component of diagnostic resilience. In the early phases of the pandemic, rapid assay development and emergency use authorizations prioritized speed over scale, but the intervening years have emphasized robustness, supply continuity, and integration with clinical workflows. This evolution has left the industry with a layered ecosystem of consumables, instruments, and kits designed for diverse settings from centralized laboratories to decentralized point-of-care sites.

As public health priorities shift toward endemic management, stakeholders across clinical testing, research, self-testing, and surveillance applications are demanding solutions that balance sensitivity, usability, and cost efficiency. Detection technologies such as antibody, antigen, and loop-mediated isothermal amplification (LAMP) assays are now assessed not only on analytic performance but on manufacturability, distribution logistics, and regulatory stability. Concurrently, sample collection methods including nasopharyngeal swabs, oropharyngeal swabs, and saliva have prompted iterative improvements in kit design and user instructions to reduce variability and enable wider adoption across diagnostic centers, home care environments, and hospital settings.

The introduction sets the stage for deeper analysis by framing these dynamics within the operational realities of manufacturers, distributors, clinical adopters, and public health authorities. It highlights the central trade-offs organizations face: the need to move beyond emergency deployment models toward sustainable, scalable business and supply chain practices while preserving rapid responsiveness to epidemiological shifts. This balance underpins the subsequent sections, which detail transformative shifts, policy impacts, segmentation nuances, regional patterns, competitive behavior, actionable recommendations, and the methodological approach underpinning the insights presented.

A strategic analysis of the major structural shifts reshaping diagnostic workflows, supply resilience, and technology convergence that redefine proof-of-concept testing

The detection PoC kit environment has been reshaped by several transformative shifts that together redefine how stakeholders approach testing strategy and product development. First, decentralization of diagnostic workflows has become a central imperative. Health systems and private providers increasingly prefer PoC solutions that deliver reliable results outside traditional laboratories, which encourages manufacturers to prioritize user-centric design, simplified sample collection, and integration with digital reporting platforms. Over time, regulatory agencies have adapted pathways for such decentralized tools, which in turn speeds adoption but also raises expectations for post-market surveillance and real-world performance evidence.

Second, supply chain resilience has emerged as a strategic cornerstone. The pandemic exposed single-source dependencies for critical components such as reagents, swabs, and electronic assay modules, prompting investment in diversified sourcing, regional manufacturing capacity, and inventory strategies that buffer against disruption. Third, technology convergence is accelerating: lateral flow immunoassays, antigen detection formats, antibody serology, and LAMP-based nucleic acid amplification are being engineered with complementary strengths to address different clinical and surveillance needs. This technological pluralism enables more tailored diagnostic pathways, but it also complicates procurement and requires new frameworks for comparative evaluation.

Fourth, data integration and interoperability have come to the fore. The utility of PoC testing is amplified when results feed effortlessly into electronic health records, public health dashboards, and patient-facing applications. As a result, software and digital infrastructure partnerships are now integral to product value propositions. Lastly, commercial models have diversified beyond direct sales to include subscription services for reagent replenishment, platform-as-a-service offerings for instrument access, and bundled solutions that combine test kits with telehealth and care navigation. Together, these shifts transform PoC kits from isolated consumables into nodes within broader clinical, logistical, and digital ecosystems.

A rigorous assessment of how tariff-driven trade dynamics are reshaping procurement, manufacturing localization, and cost structures across the diagnostic supply chain

The introduction of heightened tariff measures has a cascading impact across the COVID-19 detection PoC kit value chain, affecting raw materials, finished products, and cross-border distribution strategies. Tariffs alter landed costs for consumables and instruments, prompting manufacturers and procurement teams to reassess sourcing strategies and inventory planning. For manufacturers that rely on specialized components produced abroad, tariffs can incentivize nearshoring and the development of alternate supplier relationships, which in turn can improve long-term resilience but may require near-term capital investment and process qualification.

From a commercial perspective, increased import costs compress margins for suppliers unless offset by price adjustments further downstream. Buyers such as hospitals and diagnostic centers face a tension between cost containment and the need to secure reliable supply, leading some organizations to consolidate suppliers or negotiate longer-term contracts to stabilize unit costs and delivery schedules. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies may reconfigure stocking policies and order cycles to mitigate cost volatility and preserve service continuity.

Policy responses to tariff regimes also shape market behavior. Governments may pair tariffs with incentives for domestic manufacturing, offering grants or tax benefits that accelerate regional production capacity. These incentives can create a bifurcated landscape where high-volume standardized products are localized while niche, specialized reagents continue to be imported. The cumulative effect is an industry in transition: operational decisions increasingly prioritize supply chain adaptability and regulatory compliance, and strategic planning must incorporate scenarios that account for tariff-driven cost differentials and their implications for procurement, pricing, and market access.

An integrated segmentation-driven perspective revealing where product design, regulatory evidence, and distribution strategies intersect to maximize adoption and clinical utility

Segmentation analysis provides a framework to understand where innovation, adoption, and commercial opportunity intersect within the PoC kit landscape. When viewed through the lens of product type-consumables, instruments, and kits-distinct operational and commercial considerations emerge. Consumables demand high-volume, repeatable supply and tight quality controls, instruments require capital expenditure justification and lifecycle support, and kits combine reagents and instructions in formats optimized for specific use environments. Each category follows different purchasing cycles and support needs, which in turn affects go-to-market strategies for suppliers.

Application-based segmentation-clinical testing, research, self-testing, and surveillance-highlights differences in performance requirements and user experience. Clinical testing prioritizes validated sensitivity and integration with clinical workflows, research emphasizes flexibility and assay customization, self-testing demands simplicity and robust user instructions to maintain accuracy outside professional settings, and surveillance systems focus on throughput and cost efficiency for population-level monitoring. These application distinctions influence how detection technologies are positioned and validated.

Detection technology segmentation across antibody, antigen, and LAMP modalities reveals divergent use cases and validation pathways. Antibody tests are informative for seroprevalence and past exposure, antigen assays are optimized for rapid detection of active infection with a balance of speed and sensitivity, and LAMP-based approaches offer portable nucleic acid amplification without the complexity of traditional PCR, making them attractive for decentralized settings. Sample type segmentation-nasopharyngeal swab, oropharyngeal swab, and saliva-affects user experience, biosafety considerations, and analytic sensitivity, and choices among these types influence kit design and instructions for use.

End user segmentation into diagnostic centers, home care, and hospitals underscores varying procurement models and technical support expectations. Diagnostic centers often demand batch testing throughput and validated assay comparability, home care prioritizes ease of use and clear interpretability, while hospitals require solutions that integrate into inpatient care pathways with high reliability. Distribution channel segmentation encompassing hospital pharmacy, online pharmacy, and retail pharmacy speaks to accessibility and patient behavior; online channels expand reach and convenience but raise questions about proper storage and guidance, whereas hospital pharmacies anchor medically supervised distribution. Synthesizing these segmentation lenses unveils where product development should target improvements in usability, regulatory evidence, supply planning, and digital integration to meet the specific needs of each stakeholder group.

A nuanced regional synthesis explaining how regulatory frameworks, manufacturing capacity, and healthcare delivery models drive differential adoption of PoC diagnostic solutions

Regional dynamics exert a profound influence on how PoC diagnostic products are developed, regulated, and deployed. In the Americas, heterogeneous regulatory frameworks coexist with sophisticated private healthcare networks and significant purchasing power, which accelerates adoption of advanced point-of-care instruments while also creating pockets of demand for affordable self-testing and surveillance tools. The region's large domestic manufacturing base can be leveraged to mitigate supply chain disruptions, yet disparities in access across urban and rural settings persist and require differentiated distribution approaches.

In Europe, Middle East & Africa, regulatory harmonization efforts and collaborative public health initiatives drive demand for interoperable testing solutions that can be scaled across multiple health systems. The region features a mix of high-volume centralized laboratory capability and emerging decentralized testing programs, particularly where surveillance infrastructure is being strengthened. Local procurement policies and reimbursement models vary, influencing which technologies gain traction and how suppliers structure market entry and partnership strategies.

Asia-Pacific presents a diverse ecosystem ranging from high-capacity manufacturing hubs to rapidly expanding community testing programs. Strong manufacturing ecosystems in several countries support both domestic supply and export-oriented production, and regulatory authorities have shown flexibility in approving innovative diagnostic pathways. Adoption of self-testing formats and digital integration in healthcare delivery is accelerating in urban centers, while rural and remote areas necessitate robust, low-resource-compatible solutions. Across all regions, cross-border collaboration, public-private partnerships, and targeted investment in local production capacity will shape the availability and sustainability of PoC diagnostics, with regional priorities guiding the mix of technologies, sample modalities, and distribution channels deployed.

An evidence-based examination of how strategic partnerships, platform modularity, and total-solution offerings are redefining competitive advantage in diagnostic development

Competitive behavior among firms in the PoC detection space is characterized by rapid product iteration, strategic partnerships, and flexible commercial models. Manufacturers are increasingly pursuing modular platform strategies that allow for quick reconfiguration of assays and reagents to respond to shifts in pathogen biology or market demand. Strategic partnerships with reagent suppliers, contract manufacturers, and software integrators have become central to accelerating time-to-market and scaling distribution capabilities.

Collaboration between diagnostic developers and healthcare providers is another prevalent trend, where early clinical validation and feedback loops inform iterative design improvements. Licensing arrangements and joint ventures enable companies to extend geographic reach without assuming full manufacturing risk, and supply agreements with major institutional buyers help stabilize demand. At the same time, smaller innovators focus on niche applications or unique detection chemistries to differentiate their offerings, often positioning for acquisition or co-development with larger players.

Commercial differentiation increasingly relies on the total solution: assay performance coupled with instrument serviceability, reagent logistics, user training, and digital result management. Firms that invest in post-market support, clear training materials for non-laboratory users, and evidence generation in real-world settings strengthen long-term adoption. Overall, the competitive landscape rewards agility, depth of partnerships, and the ability to provide validated, user-friendly solutions across varied care environments.

Practical strategic recommendations for leaders to build resilient supply chains, enhance user-focused design, and align commercial models with evolving healthcare demands

Industry leaders should pursue a multi-pronged approach that prioritizes supply resilience, user-centered design, and strategic commercialization to capitalize on evolving demand for PoC diagnostics. First, diversify supply chains to reduce single-source dependencies by qualifying alternate suppliers, enabling dual sourcing for critical reagents and components, and investing in regional manufacturing capabilities. This reduces exposure to trade disruptions and tariff volatility while supporting faster response to localized surges in demand.

Second, focus on product usability across varied end users by simplifying sample collection, enhancing instructions for non-professional administration, and embedding fail-safes that reduce user error. Prioritizing formats that accommodate nasopharyngeal, oropharyngeal, and saliva specimens can broaden use cases and improve user acceptance. Third, strengthen digital integration to ensure seamless reporting into clinical records and public health systems, which enhances the value proposition for institutional buyers and supports surveillance objectives.

Fourth, adopt flexible commercial models including reagent replenishment subscriptions and instrument-as-a-service to lower barriers to adoption for smaller facilities. Fifth, engage proactively with regulators and payers to establish evidence generation plans that demonstrate real-world effectiveness in distinct applications such as clinical testing, research, self-testing, and surveillance. Finally, cultivate partnerships across distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies to align stocking practices, training, and supply visibility. These coordinated actions will position organizations to deliver resilient, scalable solutions that meet both clinical and public health needs.

A transparent methodology that blends primary stakeholder interviews and rigorous secondary verification to produce actionable, ethically sourced insights without numeric market estimations

The research methodology underpinning these insights combined structured primary research with systematic secondary analysis to ensure robust and verifiable findings. Primary inputs included semi-structured interviews with stakeholders across the value chain-product developers, procurement officers, clinical users, distribution partners, and regulatory advisors-to capture operational realities, adoption drivers, and unmet needs. These interviews were designed to elicit practical decision criteria and real-world constraints that influence procurement and deployment choices.

Secondary analysis synthesized regulatory guidance, peer-reviewed literature, technical white papers, and publicly available policy documents to contextualize technological performance characteristics and regional regulatory environments. Data triangulation was applied to validate qualitative insights against multiple sources, reducing bias and enhancing reliability. Where appropriate, scenario analysis was employed to evaluate how changes such as tariff adjustments or supply interruptions could affect strategic decisions, focusing on operational levers rather than numerical forecasts.

Limitations include rapidly evolving epidemiological contexts and emerging technological innovations that may shift priorities; therefore, findings emphasize durable strategic considerations and process-oriented recommendations. Ethical considerations were observed in primary research by anonymizing proprietary information and securing consent for participation. The methodology reflects a pragmatic balance between depth of qualitative insight and breadth of secondary evidence to produce actionable guidance for stakeholders across the PoC diagnostic ecosystem.

A succinct conclusion synthesizing strategic imperatives across technology, supply resilience, and user-access considerations to inform sustainable decision-making

In summary, the COVID-19 PoC detection landscape has matured into a complex ecosystem where technology, supply chains, regulation, and user experience interact to determine commercial and public health outcomes. The emphasis has shifted from emergency deployment to sustainable, resilient models that support decentralized testing, robust surveillance, and integration with healthcare delivery systems. Segmentation lenses across product type, application, detection technology, sample type, end user, and distribution channel reveal targeted opportunities for innovation and strategic investment.

Regional dynamics and policy instruments, including trade measures and incentives for local production, will continue to influence where and how solutions are manufactured and distributed. Competitive advantage will accrue to organizations that combine modular product platforms, strategic partnerships, and comprehensive service offerings with clear evidence of real-world performance. Ultimately, the most successful strategies will align technical excellence with pragmatic considerations of supply resilience, user accessibility, and regulatory engagement to ensure diagnostic tools reliably serve both clinical care and public health objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Detection PoC Kits Market, by Product Type

  • 8.1. Consumables
  • 8.2. Instruments
  • 8.3. Kits

9. COVID-19 Detection PoC Kits Market, by Detection Technology

  • 9.1. Antibody
  • 9.2. Antigen
  • 9.3. Lamp

10. COVID-19 Detection PoC Kits Market, by Sample Type

  • 10.1. Nasopharyngeal Swab
  • 10.2. Oropharyngeal Swab
  • 10.3. Saliva

11. COVID-19 Detection PoC Kits Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. COVID-19 Detection PoC Kits Market, by Application

  • 12.1. Clinical Testing
  • 12.2. Research
  • 12.3. Self Testing
  • 12.4. Surveillance

13. COVID-19 Detection PoC Kits Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Home Care
  • 13.3. Hospitals

14. COVID-19 Detection PoC Kits Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. COVID-19 Detection PoC Kits Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. COVID-19 Detection PoC Kits Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States COVID-19 Detection PoC Kits Market

18. China COVID-19 Detection PoC Kits Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Aurora Biomed Inc.
  • 19.7. Becton Dickinson and company
  • 19.8. BGI Group
  • 19.9. BioFire Diagnostics
  • 19.10. bioMerieux SA
  • 19.11. Cerba HealthCare S.A.S. by EQT
  • 19.12. Co-Diagnostics, Inc.
  • 19.13. Convergent Technologies GmbH & Co. KG
  • 19.14. Cue health Inc.
  • 19.15. DiaSorin S.p.A.
  • 19.16. Drummond Scientific Company
  • 19.17. F. Hoffmann-La Roche AG
  • 19.18. Hologic, Inc.
  • 19.19. Mylab Discovery Solutions Pvt. Ltd.
  • 19.20. Quest Diagnostics
  • 19.21. Quidel Corporation
  • 19.22. SD Biosensor Inc.
  • 19.23. Seegene, Inc
  • 19.24. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 DETECTION POC KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COVID-19 DETECTION POC KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY LAMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY LAMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY LAMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CLINICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CLINICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CLINICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SELF TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SELF TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SELF TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)